全蝎蜈蚣颗粒剂治疗难治性哮喘的临床疗效研究
|
摘要
[目的]探索全蝎蜈蚣颗粒剂治疗难治性哮喘的临床疗效。[方法] 78例难治性哮喘患者被随机分为对照组和治疗组。两组患者均给予沙美特罗/氟替卡松吸入治疗,对照组再给予噻托溴铵吸入,治疗组则给予全蝎蜈蚣中药颗粒剂治疗,共计12周。观察治疗前后两组哮喘控制测试(ACT)、肺功能、短效缓解药物用量、呼出气一氧化氮浓度(FeNO)以及血常规、肝肾功能等安全性指标。[结果]治疗后两组ACT评分升高、短效药物使用量减少,FeNO浓度下降,治疗组改善程度明显优于对照组(P<0.05)。两组治疗后肺功能也较治疗前改善,但两组间无统计学差异(P>0.05)。两组治疗后各项安全性指标均在正常范围内。[结论]全蝎蜈蚣中药颗粒剂(每日3 g,连续12周)治疗难治性哮喘可改善临床症状和肺功能,减轻气道炎症,且未发现不良反应。
[Objective] To study the Clinical efficacy of scorpion and centipede granule in the treatment of refractory asthma. [Methods]The 78 patients with refractory asthma were randomly assigned to the control and treatment groups. Both groups were treated with amitol/fluticasone inhalation,the control group were given tiotropium bromide inhalation in addition,while the treatment group were given scorpion and centipede Chinese medicine granule. Both groups were treated for 12 weeks. Asthma control test(ACT),lung function,short-term remission drug dosage,exhaled nitric oxide concentration(FeNO)and safety indicators such as blood test and liver and kidney function in the two groups were observed before and after treatment. [Results] After treatment,ACT score increased,short-acting drug use decreased,and FeNO concentration decreased in both two groups. But the improvement degree of the treatment group was significantly better than the control group(P<0.05). Lung function was also improved after treatment in the two groups,but there was no significant difference between the two groups(P >0.05). All the safety indicators were in the normal range after treatment in both groups.[Conclusion] Treatment of refractory asthma with scorpion and centipede granule(3 g/day,for 12 weeks) can improve clinical symptoms and lung function,reduce airway inflammation,and has no toxic and side effects.
[Objective] To study the Clinical efficacy of scorpion and centipede granule in the treatment of refractory asthma. [Methods]The 78 patients with refractory asthma were randomly assigned to the control and treatment groups. Both groups were treated with amitol/fluticasone inhalation,the control group were given tiotropium bromide inhalation in addition,while the treatment group were given scorpion and centipede Chinese medicine granule. Both groups were treated for 12 weeks. Asthma control test(ACT),lung function,short-term remission drug dosage,exhaled nitric oxide concentration(FeNO)and safety indicators such as blood test and liver and kidney function in the two groups were observed before and after treatment. [Results] After treatment,ACT score increased,short-acting drug use decreased,and FeNO concentration decreased in both two groups. But the improvement degree of the treatment group was significantly better than the control group(P<0.05). Lung function was also improved after treatment in the two groups,but there was no significant difference between the two groups(P >0.05). All the safety indicators were in the normal range after treatment in both groups.[Conclusion] Treatment of refractory asthma with scorpion and centipede granule(3 g/day,for 12 weeks) can improve clinical symptoms and lung function,reduce airway inflammation,and has no toxic and side effects.
引文
[1] Hoskins G,Mc Cowan C,Neville RG,et al. Risk factors and costs associated with an asthma attack[J].Thorax,2000,(55):19-24.
[2] Strek ME. Difficult asthma[J].Proc Am Thorac Soc,2006,3(1):116-123.
[3]中华医学会呼吸病学分会哮喘学组.难治性哮喘诊断与处理专家共识[J].中华结核和呼吸杂志,2010,33(8):572-577.
[4] ATS/ERS. ATS ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nosal nitric oxide[J].Am J Respir Crit Care Med,2005,(171):912.
[5] Iwamoto H,Yokoyama A,Shiota N,et al.Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype[J]. J Eur Respir J,2008,31(6):1379-1380.
[6] Kerstjens HA,Engel M,Dahl R,et al. Tiotropium in asthma poorly controlled with standard combination therapy[J].N Engl J Med,2012,367(13):1198-1207.
[7] Reddel HK,Taylor DR,Bateman ED,et al. An official American Thoracic Society/European Respiratory Society statement:asthma control and exacerbations:standardizing endpoints for clinical asthma trials and clinical practice[J].Am J Respir Crit Care Med,2009,180(1):59-99.
[8]李海燕,杨佩兰,黄海茵,等.全蝎-蜈蚣药对对哮喘模型大鼠气道炎症及气道重塑的影响[J].中国实验方剂学杂志,2013,19(1):206-210.
[9]吴春红,梁刚,张红,等.少棘蜈蚣最细粉小鼠急性毒性和大鼠3月慢性毒性研究[J].中药药理与临床,2017,33(5):115-119.
[10]孔天翰,肖桂元,周少雄,等.7种蝎毒的高效液相分析及毒理学研究[J].河南医科大学学报,1999,34(1):63-66.
[11]徐龙生,冯勤丽,张小平,等.蜈蚣全蝎散镇痛效应及毒副作用实验研究[J].中华全科医学,2018,16(3):346-348.
[2] Strek ME. Difficult asthma[J].Proc Am Thorac Soc,2006,3(1):116-123.
[3]中华医学会呼吸病学分会哮喘学组.难治性哮喘诊断与处理专家共识[J].中华结核和呼吸杂志,2010,33(8):572-577.
[4] ATS/ERS. ATS ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nosal nitric oxide[J].Am J Respir Crit Care Med,2005,(171):912.
[5] Iwamoto H,Yokoyama A,Shiota N,et al.Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype[J]. J Eur Respir J,2008,31(6):1379-1380.
[6] Kerstjens HA,Engel M,Dahl R,et al. Tiotropium in asthma poorly controlled with standard combination therapy[J].N Engl J Med,2012,367(13):1198-1207.
[7] Reddel HK,Taylor DR,Bateman ED,et al. An official American Thoracic Society/European Respiratory Society statement:asthma control and exacerbations:standardizing endpoints for clinical asthma trials and clinical practice[J].Am J Respir Crit Care Med,2009,180(1):59-99.
[8]李海燕,杨佩兰,黄海茵,等.全蝎-蜈蚣药对对哮喘模型大鼠气道炎症及气道重塑的影响[J].中国实验方剂学杂志,2013,19(1):206-210.
[9]吴春红,梁刚,张红,等.少棘蜈蚣最细粉小鼠急性毒性和大鼠3月慢性毒性研究[J].中药药理与临床,2017,33(5):115-119.
[10]孔天翰,肖桂元,周少雄,等.7种蝎毒的高效液相分析及毒理学研究[J].河南医科大学学报,1999,34(1):63-66.
[11]徐龙生,冯勤丽,张小平,等.蜈蚣全蝎散镇痛效应及毒副作用实验研究[J].中华全科医学,2018,16(3):346-348.